Cluster B: 7 High Throughput Screening

集群 B：7 高通量筛选

基本信息

批准号：
9914246
负责人：
Meng Wu
金额：
$ 6.9万
依托单位：
UNIVERSITY OF IOWA
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/9914246
关键词：
Antibodies Antisense Oligonucleotides Applications Grants Automation Biological Biological Assay Biological Response Modifier Therapy Biology Biomedical Research Cancer Biology Cancer Center Support Grant Cell Differentiation process Cell Line Cells Chemicals Clinical Collection Comprehensive Cancer Center Data Set Detection Excretory function FDA approved Flow Cytometry Fluorescence Fluorescence Resonance Energy Transfer Fostering Funding Generations Genes Genetic Genomics Shared Resource Goals Grant Lead Libraries Ligands Malignant Neoplasms Metabolism Microscopy Mission Molecular Molecular Probes Neurites Pathway Analysis Pathway interactions Patients Pharmaceutical Chemistry Pharmaceutical Preparations Phenotype Phosphotransferases Process RNA Interference Reader Research Research Design Research Personnel Resources Robotics Running Services Signal Pathway Small Interfering RNA System Techniques Testing Therapeutic Therapeutic antibodies Tissues Toxic effect United States National Institutes of Health Universities Walking Xenograft procedure absorption cancer cell cancer therapy cell motility chemical synthesis combinatorial confocal imaging data management design drug development drug discovery druggable target genetic approach genome-wide high throughput screening imaging system in vitro testing instrumentation luminescence member miniaturize new therapeutic target novel novel strategies personalized cancer therapy pre-clinical preclinical development protein expression research facility screening small molecule small molecule libraries small molecule therapeutics therapeutic development trafficking transcription factor

项目摘要

The UI High Throughput Screening Core (HTS) is a new Holden Comprehensive Cancer Center (HCCC) shared research resource that provides a high-throughput platform integrating robotics, detection systems, chemical /biologics libraries, data management, and expertise. HTS provides HCCC members with scalable early, pre-clinical development of therapeutics, including small molecule therapeutics, antibodies, siRNAs, antisense oligonucleotides and other biologics including patient-derived cell therapeutics. It also supports high throughput screening for studies exploring the biology of cancer. The automatic, miniaturized and parallel high-throughput approaches foster hit and lead generation for drug discovery and development through screening of systematic, unbiased large chemical/biologics libraries. These strategies also facilitate molecular probe discovery for mechanism-of-action (MOA) studies of chemical biology through screening of focused intellectually designed compound collections. In addition, these high- throughput approaches aid the interrogation of cells, especially those derived from patients. The HTS was established in 2012 by university sponsors including the HCCC and an NIH S10 Shared Instrumentation grant funding. HTS is equipped to perform high-throughput screening in 96-, 384- and 1536- well formats, with plate reader detection (Perkin-Elmer EnVision) using absorbance, fluorescence and luminescence, including advanced FRET and BRET techniques. HTS can also perform high content screening (HCS, Perkin-Elmer Operetta Confocal Imaging System) to detect and quantify phenotypic changes, i.e. cell differentiation, cell migration, neurite outgrowth, and target trafficking; or by fluorescence intensities for target protein expression, transcription factor or signaling pathway analysis. Systems available in the HTS are integrated with robotics for plate handling and assay execution, suitable for small- or large-scale compound library screens with “walk-away” levels of automation. HTS currently holds five “small molecule” libraries containing approximately 140,000 compounds. In addition, HTS is in the process of determining the need and feasibility of obtaining a biologics library, i.e. genome-wide siRNA, antibodies, and diverse cell lines. Overall, HTS is a shared research resource focused on scalable screening approaches for drug discovery and development, and molecular probe discovery for mechanism-of-action studies for cancer investigators across campus and beyond.

UI高通量筛选核心（HTS）是一个新的Holden综合癌症中心（HCCC）共享研究资源，提供一个集成机器人技术，检测系统的高通量平台，化学 /生物制剂图书馆，数据管理和专业知识。 HTS为HCCC成员提供可扩展的早期的治疗前临床前发育，包括小分子治疗，抗体，siRNA，反义寡核苷酸和其他生物制剂，包括患者衍生的细胞疗法。它也支持高研究探索癌症生物学的研究吞吐量筛查。自动，微型和平行的高通量方法促进了药物的命中和潜在客户产生通过筛选系统的，公正的大型化学/生物制剂图书馆，发现和开发。这些策略还促进了分子探针发现化学机理（MOA）研究生物学通过筛选重点的智力设计的复合收集。另外，这些高吞吐量方法有助于细胞的询问，尤其是从患者中得出的细胞。 HTS由大学赞助商于2012年成立，包括HCCC和NIH S10共享仪器赠款资金。 HTS等同于在96、384和1536-中进行高通量筛查。井格式，使用吸收，荧光和发光，包括高级品格和BRET技术。 HTS也可以执行高内容筛选（HCS，Perkin-Elmer Operaetta共聚焦成像系统）检测和量化表型变化，即细胞分化，细胞迁移，神经落出和目标贩运；或通过目标的荧光强度蛋白质表达，转录因子或信号通路分析。 HTS中可用的系统是与机器人技术集成用于板的处理和测定执行，适用于小型或大型化合物具有“步行”自动化水平的图书馆屏幕。 HTS目前拥有五个“小分子”库包含大约140,000种化合物。此外，HTS正在确定需求和获得生物制剂文库的可行性，即全基因组siRNA，抗体和各种细胞系。总体而言，HTS是一种共享的研究资源，专注于可扩展的筛查方法，以进行药物发现和开发和分子探针发现癌症研究者的行动机理研究校园及以后。